PHARMACOLOGY OF OPTIMARK IN PATIENTS WITH CNS OR LIVER PATHOLOGY

本I期研究的主要目的是评价 新开发的MRI造影剂的剂量相关效应。 目前使用的药物剂量为0.1至0.3 mmol/kg。 这种新的代理商是一种非离子，细胞外，线性钆基 将以0.1、0.3和0.5 mmol/kg的剂量测试螯合物。 受试者将是已知患有脑部、脊柱和/或肝脏疾病的患者， 并被选为代表患者类型， 目前正在使用对比MRI。 这项研究于1997年9月完成。

The primary aim of this Phase I study is to evaluate the pharmacological dose-related effects of a newly developed contrast agent for use with MRI. Agents currently being used are available in doses of 0.1 to 0.3 mmol/kg. This new agent is a non-ionic, extracellular, linear gadolinium based chelate that will be tested in doses of 0.1, 0.3, and 0.5 mmol/kg. Subjects will be patients with known brain, spine, and/or liver disease, and were chosen to be representative of the type of patient for which contrast MRI is currently being used. This study was completed in September, 1997.